Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
- Conditions
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 126
- Registration Number
- NCT04999969
- Locations
- 🇪🇸
Research Site, Pamplona, Spain
TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 33
- Registration Number
- NCT04988945
- Locations
- 🇭🇰
Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong
🇭🇰The University of Hong Kong, Hong Kong, Hong Kong
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
- Conditions
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT04985851
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 35
- Registration Number
- NCT04982549
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
- Conditions
- Interventions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 677
- Registration Number
- NCT04960709
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 6
- Registration Number
- NCT04951115
- Locations
- 🇺🇸
New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
🇺🇸New York-Presbyterian Queens, Flushing, New York, United States
Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT04945720
- Locations
- 🇨🇳
Department of Minimally Invasive and Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT04940286
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 60
- Registration Number
- NCT04918186
- Locations
- 🇨🇦
The Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
🇨🇦Odette Cancer Centre, Toronto, Ontario, Canada
SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 37
- Registration Number
- NCT04913480
- Locations
- 🇭🇰
Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.